FindTrial
Sign In

Monitoring ADR Of Pemetrexed Platinum Chemotherapy in NSCLC

Monitoring Adverse Drug Reactions Of Pemetrexed Platinum Doublet Chemotherapy in patients with non-squamous non-small cell lung cancer or mesothelioma in Tata Memorial Centre - ADR-NSCLC

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/10/009960
Enrollment
100
Registered
2017-10-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms Health Condition 2: null- NSCLC patients and Mesothelioma patients

Interventions

None listed

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with histologically confirmed NSCLC or mesothelioma 2. Patients receiving first cycle of Pemtrexed + Platinum Doublet Chemotherapy

Exclusion criteria

Exclusion criteria: Patients having non-compliance to treatment schedule at Tata Memorial Centre Patients not willing to give written informed consent

Design outcomes

Primary

MeasureTime frame
Incidence and severity of Adverse Drug ReactionsTimepoint: After the study completion—

Secondary

MeasureTime frame
Frequency of Grade 3/4 ADR Median Duration of Grade3/4 ADR Causality assessment using Naranjo scaleTimepoint: At the end of each cycle of chemotherapy—

Countries

India

Contacts

Public ContactDr K Manjunath Nookala

ACTREC, Tata Memorial Centre

nk.manjunath@gmail.com02227405130

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026